Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma
Neoadjuvant Therapy
Tumor budding
DOI:
10.1111/his.15192
Publication Date:
2024-04-17T09:54:26Z
AUTHORS (16)
ABSTRACT
Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility TB assessment setting treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (56)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....